Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R-95845
- Development stage
- Preclinical
- Modality
- Small Molecules
01
Overview
R-95845 is an experimental small molecule inhibitor of HIV‑1 reverse transcriptase. It has not been approved for clinical use and has not advanced beyond preclinical or very early clinical development. Its primary mechanism is the inhibition of the reverse transcriptase enzyme essential for HIV replication. The compound’s chemical formula is C17H16Br2N2O2 and it is classified as a benzeneacetamide derivative[1][3][4].
- Other names
- Benzeneacetamide, alpha-((2-acetyl-5-methylphenyl)amino)-2,6-dibromo-,(S)-(2S)-2-((2-acetyl-5-methylphenyl)amino)-2-(2,6-dibromophenyl)acetamideUNII-X1KA97Q99GUNII-X-1KA97Q99GUNII-X 1KA97Q99GCAS 163435-77-6CAS163435-77-6CAS-163435-77-6
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on R-95845.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R-95845.